Insulin resistance and non-alcoholic fatty liver disease: a review of the pathophysiology and the potential targets for drug actions

Taoreed Adegoke Azeez(1*), Morenike Osundina(2)
(1) Endocrinology, Metabolism and Diabetes Unit Department of Medicine, University College Hospital, Ibadan, Nigeria
(2) Gatroenterology & Hepatology Unit, Department of Medicine, University College Hospital, Ibadan, Nigeria.
(*) Corresponding Author
Abstract
Keywords
Full Text:
PDFReferences
- Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am 2004; 33(2):283-303. https://doi.org/10.1016/j.ecl.2004.03.002
- Wilcox G. Insulin and insulin resistance. Clin Biochem Rev 2005; 26(2): 19-39.
- Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2002; 17 Suppl(1):S186-90 https://doi.org/10.1046/j.1440-1746.17.s1.10.x
- Maurice J, Manousou P. Non-alcoholic fatty liver disease. Clin Med (Lond) 2018; 18(3): 245-50. https://doi.org/10.7861/clinmedicine.18-3-245
- Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64(1):73-84. https://doi.org/10.1002/hep.28431
- Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015; 149(2):367-78. https://doi.org/10.1053/j.gastro.2015.04.005
- Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362(18):1675-85. https://doi.org/10.1056/NEJMoa0907929
- Bratanova-Tochkova TK, Cheng H, Daniel S, Gunawardana S, Liu YJ, Mulvaney-Musa J, et al. Triggering and augmentation mechanisms, granule pools, and biphasic insulin secretion. Diabetes 2002; 51(Suppl 1):S83-S90. https://doi.org/10.2337/diabetes.51.2007.S83
- Soria B, Quesada I, Ropero AB, Pertusa JA, Martín F, Nadal A. Novel players in pancreatic islet signaling: from membrane receptors to nuclear channels. Diabetes 2004; 53(Suppl 1):S86-91. https://doi.org/10.2337/diabetes.53.2007.S86
- Kido Y, Nakae J, Accili D. Clinical review 125: the insulin receptor and its cellular targets. J Clin Endocrinol Metab. 2001; 86(3):972-9. https://doi.org/10.1210/jcem.86.3.7306
- Withers DJ, White M. Perspective: the insulin signaling system-a common link in the pathogenesis of type 2 diabetes. Endocrinology 2000; 141(6):1917-21. https://doi.org/10.1210/endo.141.6.7584
- Burks DJ, White MF. IRS proteins and beta-cell function. Diabetes 2001; 50(Suppl 1):S140-5. https://doi.org/10.2337/diabetes.50.2007.S140
- Smith U. Impaired ('diabetic') insulin signaling and action occur in fat cells long before glucose intolerance--is insulin resistance initiated in the adipose tissue? Int J Obes Relat Metab Disord 2002; 26(7):897-904. https://doi.org/10.1038/sj.ijo.0802028
- Samuel VT, Shulman GI. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Invest 2016; 126(1):12-22. https://doi.org/10.1172/JCI77812
- Devaraj S, Rosenson RS, Jialal I. Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status. Endocrinol Metab Clin North Am 2004; 33(2):431-53. https://doi.org/10.1016/j.ecl.2004.03.008
- Herman MA, Peroni OD, Villoria J, Schön MR, Abumrad NA, Blüher M, et al. A novel ChREBP isoform in adipose tissue regulates systemic glucose metabolism. Nature 2012; 484(7394):333-8. https://doi.org/10.1038/nature10986
- Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89(6):2548-56. https://doi.org/10.1210/jc.2004-0395
- Asano T, Watanabe K, Kubota N, Gunji T, Omata M, Kadowaki T, et al. Adiponectin knockout mice on high fat diet develop fibrosing steatohepatitis. J Gastroenterol Hepatol 2009; 24(10):1669-76. https://doi.org/10.1111/j.1440-1746.2009.06039.x
- Carr RM, Oranu A, Khungar V. Non-alcoholic fatty liver disease: pathophysiology and management. Gastroeneterol Clin North Am 2016; 45(4):639-52. https://doi.org/10.1016/j.gtc.2016.07.003
- Yu J, Marsh S, Hu J, Feng W, Wu C. The pathogenesis of nonalcoholic fatty liver disease: interplay between diet, gut microbiota, and genetic background. Gastroenterol Res Pract 2016; 2016:2862173. https://doi.org/10.1155/2016/2862173
- Dumas ME, Kinross J, Nicholson JK. Metabolic phenotyping and systems biology approaches to understanding metabolic syndrome and fatty liver disease. Gastroenterology 2014; 146(1):46-62. https://doi.org/10.1053/j.gastro.2013.11.001
- Johnson AR, Milner JJ, Makowski L. The inflammation highway: metabolism accelerates inflammatory traffic in obesity. Immunol Rev 2012; 249(1):218-38. https://doi.org/10.1111/j.1600-065X.2012.01151.x
- Barbuio R, Milanski M, Bertolo BM, Saad MJ, Velloso LA. Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet. J Endocrinol 2007; 194(3):539-50. https://doi.org/10.1677/JOE-07-0234
- Hasenour CM, Berglund ED, Wasserman DH. Emerging role of AMP-activated protein kinase in endocrine control of metabolism in the liver. Mol Cellular Endocrinol 2013; 366(2):152-62. https://doi.org/10.1016/j.mce.2012.06.018
- Day CP. Non-alcoholic fatty liver disease: current concepts and management strategies. Clin Med 2006; 6(1):19-25. https://doi.org/10.7861/clinmedicine.6-1-19
- Sharifnia T, Antoun J, Verriere TGC. Hepatic TLR4 signaling in obese NAFLD. Am J Physiol-Gastrointest Liver Physiol 2015; 309(4):G270-78. https://doi.org/10.1152/ajpgi.00304.2014
- Federico A, Zulli C, de Sio I, Del Prete A, Dallio M, Masarone M, et al. Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(45):16841-57. https://doi.org/10.3748/wjg.v20.i45.16841
- Tilg H, Moschen A. Weight loss: cornerstone in the treatment of non-alcoholic fatty liver disease. Minerva Gastroenterol Dietol 2010; 56(2):159-67.
- Zelber-Sagi S, Kessler A, Brazowsky E, Webb M, Lurie Y, Santo M et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006; 4(5):639-44. https://doi.org/10.1016/j.cgh.2006.02.004
- Wierzbicki AS, Pendleton S, McMahon Z, Dar A, Oben J, Crook MA, et al. Rimonabant improves cholesterol, insulin resistance and markers of non-alcoholic fatty liver in morbidly obese patients: a retrospective cohort study. Int J Clin Pract 2011; 65(6):713-5. https://doi.org/10.1111/j.1742-1241.2011.02683.x
- Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011; 305(16):1659-68. https://doi.org/10.1001/jama.2011.520
- Van Wagner LB, Rinella ME. The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. Therap Adv Gastroenterol 2011; 4(4):249-63. https://doi.org/10.1177/1756283X11403809
- Nseir W, Mograbi J, Ghali M. Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies. Dig Dis Sci 2012; 57(7):1773-81. https://doi.org/10.1007/s10620-012-2118-3
- Loguercio C, Federico A, Trappoliere M, Tuccillo C, de Sio I, Di Leva A, Niosi M, et al. The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci 2007; 52(9):2387-95. https://doi.org/10.1007/s10620-006-9703-2
- Imajo K, Yoneda M, Ogawa Y, Wada K, Nakajima A. Microbiota and nonalcoholic steatohepatitis. Semin Immunopathol 2014; 36(1):115-32. https://doi.org/10.1007/s00281-013-0404-6
- Barbuio R, Milanski M, Bertolo MB, Saad MJ, Velloso LA. Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet. J Endocrinol 2007; 194(3):539-50. https://doi.org/10.1677/JOE-07-0234
- Paschos P, Tziomalos K. Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment. World J Hepatol 2012; 4(12):327-31. https://doi.org/10.4254/wjh.v4.i12.327

Article Metrics


Copyright (c) 2020 Taoreed Adegoke Azeez, Morenike Osundina

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of the Medical Sciences (Berkala Ilmu Kedokteran) by Universitas Gadjah Mada is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Based on a work at http://jurnal.ugm.ac.id/bik/.